Trial record 16 of 223 for:
Open Studies | "Peripheral Vascular Diseases"
Contrast Ultrasound Perfusion Imaging in Peripheral Arterial Disease (PAD)
Verified October 2014 by Oregon Health and Science University
Information provided by (Responsible Party):
Jonathan R. Lindner, MD, Oregon Health and Science University
First received: June 20, 2011
Last updated: October 27, 2014
Last verified: October 2014
Contrast ultrasound is a technique that can quantify blood flow in the tissues of the body by ultrasound detection of microbubble contrast agents that behave in the circulation similar to red blood cells. In this study, the investigators hypothesize that contrast ultrasound of blood flow in the leg (thigh and calf) at rest and during stress produced by medications that mimic exercise (vasodilator stress) can provide information on the location and severity of peripheral vascular disease (blockages of the blood vessels in the leg). The investigators will also determine whether symptom improvement after revascularization (procedures to open up or bypass the blockages) is directly related to the improvement in blood flow.
Peripheral Arterial Disease
||Observational Model: Cohort
Time Perspective: Prospective
||Contrast Ultrasound Perfusion Imaging in Peripheral Arterial Disease
Primary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||September 2015 (Final data collection date for primary outcome measure)
Age matched control subjects without PAD
Patients with PAD
|Ages Eligible for Study:
||19 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients with peripheral arterial disease who are referred for diagnostic angiography and/or revascularization procedures
- Known or suspected PAD
- Lower extremity angiography or MRA planned or performed within 6 months
- Age <19 y.o.
- Pregnant or lactating females
- Hypersensitivity to ultrasound contrast agent, dipyridamole, or regadenoson
- Severe reactive airways disease
- Evidence right-to-left shunt (identified on screening echo)
- NYHA Class III or IV heart failure.
- Planned amputation
- Unstable coronary artery disease or severe aortic stenosis
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01377649
|Oregon Health & Science University
|Portland, Oregon, United States, 97239 |
|Contact: Jonathan R Lindner, MD 503-494-8750 firstname.lastname@example.org |
Oregon Health and Science University
No publications provided
||Jonathan R. Lindner, MD, Professor, Oregon Health and Science University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 20, 2011
||October 27, 2014
||United States: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 26, 2015
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases